Valbiotis SA
8JD
Company Profile
Business description
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
Contact
12F rue Paul VATINE
Perigny
La Rochelle17180
FRAT: +33 546286258
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
55
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.80 | 42.20 | -0.46% |
| CAC 40 | 8,181.88 | 55.35 | 0.68% |
| DAX 40 | 24,753.03 | 214.22 | 0.87% |
| Dow JONES (US) | 49,112.97 | 220.50 | 0.45% |
| FTSE 100 | 10,321.46 | 97.92 | 0.96% |
| HKSE | 26,775.57 | 611.54 | -2.23% |
| NASDAQ | 23,507.95 | 46.13 | 0.20% |
| Nikkei 225 | 52,655.18 | 667.67 | -1.25% |
| NZX 50 Index | 13,412.44 | 10.74 | -0.08% |
| S&P 500 | 6,953.59 | 14.56 | 0.21% |
| S&P/ASX 200 | 8,778.60 | 42.50 | -0.48% |
| SSE Composite Index | 4,015.75 | 102.20 | -2.48% |